1.Liraglutide, a human glucagon-like peptide-1 analogue, plays a role in reducing body weight in the patients with type 2 diabetes
Chinese Journal of Endocrinology and Metabolism 2011;27(8):703-706
Obesity is associated with numerous metabolic abnormalities, including insulin resistance and type 2 diabetes. Losing weight is an effective way of improving insulin sensitivity, thus decreasing the risk of obesityassociated diabetes and chronic cardiovascular disease. There is evidence that Liraglutide, as a human glucagon-like peptide-1 ( GLP-1 ) analogue, either using alone or combining with other glucose-lowering drugs, has effect on improving glycemic control, protecting β-cell function, and reducing body weight via inhibiting feeding behavior and delaying gastrointestinal motility. Therefore, liraglutide is a new option for treating type 2 diabetes patients.
2.DPP-4 Inhibitors: Cost-effectiveness
Chinese Journal of Endocrinology and Metabolism 2012;(11):955-958
China is the country with the biggest diabetic population in the world.Diabetes has become a heavy financial burden for diabetic patients,families,and society.This article briefly described pharmacoeconomic concepts and analysis methods,and systemically reviewed literatures in health economic data of DPP-4 inhibitors,in the hope of providing a new perspective for clinicians,researchers,and health care policy makers.
3.Liraglutide: reduction of weight and visceral fat may benefit the comprehensive management of type 2 diabetes
Chinese Journal of Endocrinology and Metabolism 2013;29(7):后插5-后插8
Weight management is an important step in the treatment and management for type 2 diabetes.Obesity,especially visceral fat accumulation,impairs the metabolism function.Excess of visceral fat is closely related to the development of insulin resistance,metabolic syndrome,type 2 diabetes,and cardiovascular disease.Liraglutide,the (GLP-1) analogue,shows its effects on glycaemic control as well as weight reduction which mainly involves reduction of visceral fat.The efficacy characteristics of liraglutide may benefit the comprehensive management of type 2 diabetes.
4.Association of adipocyte fatty acid-binding protein with cholesterol metabolism
Chinese Journal of Endocrinology and Metabolism 2015;(7):625-628
Adipocyte fatty acid-binding protein ( FABP4 ) is abundantly expressed in adipocytes and macrophages, and the physiologic function of this lipid chaperone is involved in the intracellular trafficking and targeting of fatty acids inside cell. Studies have shown that FABP4 plays a significant role in cholesterol metabolism. FABP4 can affect some key gene expression for cholesterol metabolism, thus regulate the metabolism, storage, and trafficking of cholesterol. As the development of FABP4 inhibitors, drugs targeting FABP4 are possible and can lead to a novel therapeutic strategy to prevent and treat obesity, type 2 diabetes, hypercholesterolemia, and atherosclerosis.
5.Preoperative assessment and perioperative management for metabolic surgery in obese and type 2 diabetic patients
Chinese Journal of Diabetes 2015;(9):786-791
[Summary] The incidence of obesity and obesity‐related diseases (such as T2DM) increases year by year in the world. Metabolic surgery has increasingly been applied to patients with severe obesity. Studies have indicated that metabolic surgery is effective in obesity and obesity‐related diseases. Since patients undergoing metabolic surgery are obese or severely obese ,whose physiological and pathological changes are different with those of non‐obese patients ,a comprehensive assessment and management during perioperative period and after the operation were needed. This article mainly expounds preoperative evaluation and preparation ,management of surgery process and postoperative nutrition and endocrine management.
6.Correlation between microsatellite polymorphisms in ob gene 3′ flanking region with overweight and obesity in Chinese Han ethnicity in Shanghai
Academic Journal of Second Military Medical University 2001;0(09):-
Objective:To investigate the correlation between the microsatellite polymorphisms in ob gene 3′flanking region with obesity in Chinese Han ethnicity in Shanghai.Methods: The genotypes of polymorphisms in ob gene 3′flanking region were determined by PCR in 232 Chinese Han subjects(including 130 obese patients and 102 normal controls).The clinical data,including height,weight,waist circumference,hip circumference,body mass index,waist-to hip ratio(WHR),blood glucose,serum insulin,blood lipids,and uric acid,were compared between the 2 groups.Results: No significant difference of genotype frequency(Ⅰ/Ⅰ 0.115,Ⅰ/Ⅱ 0.331,Ⅱ/Ⅱ 0.554 vs Ⅰ/Ⅰ 0.059,Ⅰ/Ⅱ 0.333,Ⅱ/Ⅱ 0.608) and allele frequency(Ⅰ 0.281,Ⅱ 0.719 vs Ⅰ 0.225,Ⅱ 0.775) of ob gene 3′flanking region was observed between the 2 groups.In obese group,patients with Ⅰ+Ⅱ genotype was associated with increased WHR compared with those with Ⅱ/Ⅱ genotype(0.91?0.05 vs 0.86?0.03,P=0.047).Logistic regression analysis showed that WHR was independently correlated with ob gene polymorphisms(P=0.042).Conclusion: Polymorphisms in ob gene 3′ flanking region are correlated with central obesity in obese patients of Chinese Han ethnicity in Shanghai.
7.Expressions of leptin receptor mRNA and neuropeptide Y mRNA in the hypothalamic arcuate nucleus of obese rat induced by high fat diet
Chinese Journal of Endocrinology and Metabolism 1986;0(03):-
The rat model of obesity was induced by high fat diet and in situ hybridization was performed with oligonucleotide probes.The results showed that expressions of leptin receptor mRNA and neuropeptide Y mRNA were significantly increased, suggesting that these increments might be related to leptin resistance.
8.Effects of high-fat diet on insulin sensitivity in rats
Journal of Xi'an Jiaotong University(Medical Sciences) 2003;0(06):-
Objective To observe the effects of high-fat diet on insulin sensitivity in rats. Methods Normal rats were fed with equicalorical high-fat diet and then treated with troglitazone. Glucose-insulin tolerance test was used to measure insulin sensitivity, blood pressure, blood glucose, insulin, endothelin, lipid, tissue glycogen and triglyceride levels. Results high-fat diet had no effect on body weight gain and blood pressure. Fasting and postprandial blood glucose levels were similar among the different groups. The levels of blood insulin, triglyceride, cholesterol and endothelin increased markedly, and the decrease in tissue glycogen level was also found. high-fat feeding caused insulin resistance after 4 weeks (K 5.63 vs. control 7.77, P
9.EFFECTS OF SIBUTRAMINE ON PLASMA NEUROPEPTIDE Y LEVELS IN PATIENTS WITH OVERWEIGHT AND SIMPLE OBESITY
Medical Journal of Chinese People's Liberation Army 1983;0(02):-
The aim of the study was to evaluate the effects of an anti obese agent, sibutramine, on plasma neuropeptide Y(NPY) levels in patients with overweight and simple obesity. 32 patients with overweight and simple obesity were assigned randomly to sibutramine group (group A) or placebo group (group B). Double blind rule was observed in the study. 16 healthy subjects served as control group (group C). Before and after six months of treatment, plasma NPY and serum insulin levels of patients in both groups were measured with radioimmunoassay (RIA). The results showed that fasting plasma NPY levels were higher in obese group than in control group before treatment .No significant difference was found between plasma NPY levels before and after the treatment with sibutramine. The study revealed that patients with overweight and simple obesity had elevated levels of plasma NPY. Sibutramine did not exert any influence on plasma NPY levels in these patients.
10.Role of SOCS-3 on leptin resistant and obesity
Academic Journal of Second Military Medical University 2001;0(09):-
The new protein suppressors of cytokine signaling(SOCS) as negative regulators of signaling pathways involve in the cellular actions of many cytokines, including leptin. It regulates intracellular signal transduction cascades such as the JAK STAT pathway. SOCS is now evident of leptin resistance and has close relation with obesity. We reviewed the structure and function of SOCS 3 and the mechanism in leptin signaling pathway,providing data for the potential effect of SOCS 3 in the treatment of obesity.